RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Valeant Pharmaceuticals International

A collection of news and information related to Valeant Pharmaceuticals International published by this site and its partners.

Top Valeant Pharmaceuticals International Articles see all

Displaying items 1-5
  • Lawsuit accuses Ackman, Valeant of insider trading in Allergan stock

    Lawsuit accuses Ackman, Valeant of insider trading in Allergan stock
    A new lawsuit accuses hedge fund manager Bill Ackman and Canadian firm Valeant Pharmaceuticals International Inc. of insider trading in Allergan Inc. stock before their unsuccessful bid to acquire the Botox maker.
  • Few Allergan execs to keep top jobs in Actavis takeover

    Few Allergan execs to keep top jobs in Actavis takeover
    The soon-to-be owner of Irvine-based Allergan Inc. announced sweeping leadership changes that pass over many current executives including the Botox maker's CEO. Irish pharmaceutical giant Actavis expects to finalize its $66-billion acquisition in the...

    Allergan sale to Actavis thwarts takeover attempt by Valeant

    Botox maker Allergan Inc., an Irvine company that started as a purveyor of eye drops and grew into one of the most respected pharmaceutical companies in the country, agreed to be acquired by Irish firm Actavis for $66 billion. The deal thwarts a...

    Allergan and Actavis drawing closer to deal

    Botox maker Allergan Inc. is closing in on a deal to be acquired by Irish company Actavis, a move that would potentially thwart a hostile takeover by Canadian company Valeant Pharmaceuticals International Inc. A deal for more than $62.5 billion could be...

    Botox maker Allergan is said to be edging closer to a sale to Actavis

    Botox maker Allergan Inc. is closing in on a deal to be acquired by Irish company Actavis, a move that would potentially thwart a hostile takeover by Canadian company Valeant Pharmaceuticals International Inc. A $62.5-billion deal could be announced...